Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

• Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
  Sponsor: Allovir
  Organ Type: All organs
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Saturday, March 30, 2024
  Other Requirements
   
• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Wednesday, June 30, 2027
  Other Requirements
  COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
   
• Interleukin 6 blockade Modifying Antibody mediated Graft INjury and eGFR decline (IMAGINE)
  Sponsor: CSL Behring
  Organ Type: Kidney
  Ages Accepted: 18 years old to 70 years old
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 2028
   
• Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)
  Sponsor: Hansa Biopharma
  Organ Type: Kidney
  Ages Accepted: ≥18 and ≤70 years
  Genders Accepted: Both male and female
  Expected Study Completion Date:  December 31, 2023 
  Other Requirements
   
• A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
  Sponsor: Novartis 
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: July 28, 2026
   
• A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
  Sponsor: Talaris Therapeutics
  Organ Type: Living Donor Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 30, 2025

   

Clinical Trials for Other Organ Types

• Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
  Sponsor: Allovir
  Organ Type: All organs
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Saturday, March 30, 2024
  Other Requirements
   
• Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Wednesday, June 30, 2027
  Other Requirements
  COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
   
• A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
  Sponsor: Novartis 
  Organ Type: Liver
  Ages Accepted: 18 years to 70 years 
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 26, 2023
   
• A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 Administered Intravenously or Subcutaneously in Healthy Subjects
  Sponsor: Veloxis Pharmaceuticals
  Organ Type: Other - Healthy Participants 
  Ages Accepted: 18 years to 65 years 
  Genders Accepted: Both male and female
  Expected Study Completion Date: Monday, October 31, 2022